For many, a walk to the mailbox is a simple, daily routine. But imagine if that short journey triggered crushing chest pain, forcing you to stop, catch your breath, and wait for the pressure to subside. This is the daily reality for hundreds of thousands of Americans living with a debilitating condition called refractory angina.
Many patients with severe chest pain have already exhausted standard, approved treatments such as medical management, stents, and bypass surgery, only for the pain to return. Their lives become limited, and they are often told there are no more options.
This frustrating reality is the driving force behind the COSIRA-II clinical trial, a groundbreaking study at Hackensack Meridian Hackensack University Medical Center evaluating an experimental device that offers a glimmer of hope for this hard-to-treat condition.
“These are patients who have been told there’s nothing more that can be done for them,” says Dr. Haroon Faraz, Medical Director of Interventional Cardiology at Hackensack University Medical Center and a principal investigator for a new clinical trial evaluating an investigational device-based option for these patients. “They are often left to manage debilitating symptoms that affect every aspect of their lives. Our participation in this trial is an attempt to change that narrative and provide access to cutting-edge solutions.”
Simple Solution To Complex Problem
The study, known as The COSIRA-II trial, is investigating the Johnson & Johnson Shockwave Coronary Sinus Reducer, a tiny, hourglass-shaped mesh device. In a minimally invasive procedure that typically takes less than 30 minutes under local anesthesia, the device is implanted in the coronary sinus, a major vein that collects blood from the heart muscle.
The device works by creating a slight narrowing, which gently increases pressure in the vein. This change in pressure is believed to help redistribute blood flow to areas of the heart muscle that are starved for oxygen, a condition known as ischemia, which is the root cause of the angina pain. Previous studies in Europe have shown that this innovative approach can provide significant symptom relief within weeks.
“The elegance of this therapy lies in its simplicity and minimally invasive nature,” explains Dr. Faraz. “For a patient who has already undergone major surgeries, the prospect of a quick procedure with the potential for significant, lasting relief is incredibly encouraging.”
Leading the Way in Cardiac Innovation
Hackensack University Medical Center’s involvement in the COSIRA-II trial underscores its commitment to leadership in cardiovascular research and patient care. The hospital is one of the select sites in the nation, and the first in New Jersey, to offer this investigational therapy, providing patients in the community with access to the latest advancements in cardiac medicine.
For so many suffering from refractory angina, this trial represents more than just a potential new treatment. It represents the possibility of reclaiming their lives, of taking that walk to the mailbox, playing with their grandchildren, and enjoying the simple pleasures that their condition has stolen from them.
Click here to learn more about Hackensack Meridian Health’s comprehensive heart care.